clinical trial · NCT04201574
Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye DiseaseALY688 0.1%ALY688 0.4%Vehicle
brief summary
Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease
started
Dec 16, 2019
primary completion
Sep 15, 2020
completion
Sep 15, 2020
last updated
Jun 22, 2023
detailed description
This is a multi-center, randomized, double-masked Phase 1/2a trial designed to evaluate the safety and tolerability of ALY688 Ophthalmic Solution in subjects with moderate to mildly severe dry eye for 8 weeks with 6 scheduled clinic visits.
official title
A Phase 1/2a, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Exploratory Activity of Two Concentrations of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol